InvAscent looks to log another exit from pharma portfolio

Premium

Healthcare-focused private equity firm InvAscent is looking to exit its more than six-year-old investment in an animal pharmaceuticals company, possibly via a secondary transaction, two people aware of the development told VCCircle.  The PE firm, which is deploying its fourth fund and moving towards the vehicle’s final closing, is planning to ......